RxDoctor Payments Data

Alison Skinner, MD

Family Medicine · Chesapeake, VANPI 1558324467

Payments from drug & device makers

$546in general payments, 2019–2025

Across 21 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dynavax Technologies Corporation$147
  • Teva Pharmaceuticals USA, Inc.$121
  • Novo Nordisk$98
  • AbbVie$35
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$29
  • AstraZeneca$25
  • plus $90 from 5 others

What the payments were for

  • Food & beverage$51194%
  • Education$356%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$546 in reported general payments places this provider in the 60th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$77,126
Medicare patients
309
Services billed
1,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide47$70,004
OzempicSemaglutide56$59,709
JanuviaSitagliptin Phosphate44$49,255
JardianceEmpagliflozin26$36,847
EliquisApixaban19$29,712
RybelsusSemaglutide27$28,167
MounjaroTirzepatide17$21,403
LinzessLinaclotide23$14,940
FarxigaDapagliflozin Propanediol11$11,906
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,959
Potassium Chloride112$3,674
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,522
Atorvastatin Calcium389$3,192
Albuterol Sulfate HfaAlbuterol Sulfate99$2,736
Amlodipine Besylate371$2,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$14$91,40764 claims
Novo NordiskOzempic, Rybelsus$98$87,87683 claims
Boehringer IngelheimJardiance$23$36,84726 claims
AbbVieLinzess, Synthroid$35$16,72853 claims
AstraZenecaFarxiga$25$11,90611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →